Fernando Martinez to Endpoint Determination
This is a "connection" page, showing publications Fernando Martinez has written about Endpoint Determination.
Connection Strength
0.937
-
Rabe KF, Halpin DMG, Han MK, Miravitlles M, Singh D, Gr?nke L, Vo? F, Martinez FJ. Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respir Res. 2020 Jul 09; 21(1):177.
Score: 0.686
-
Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2013 Jun 01; 187(11):1272.
Score: 0.105
-
Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012 May 15; 185(10):1044-8.
Score: 0.097
-
Wedzicha JA, Rabe KF, Martinez FJ, Bredenbr?ker D, Brose M, Goehring UM, Calverley PMA. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013 May; 143(5):1302-1311.
Score: 0.026
-
King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Jul 01; 184(1):92-9.
Score: 0.023